Nanotechnology for Infectious Diseases / / edited by Saif Hameed, Suriya Rehman

• Record Nr.: UNINA9910743343003321
• Pubbl/distr/stampa: Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2022
• ISBN: 9789811691904; 9811691908; 9789811691898; 9811691894
• Edizione: [1st ed. 2022.]
• Descrizione fisica: 1 online resource (638 pages)
• Collana: Biomedical and Life Sciences Series
• Disciplina: 616.90475
• Soggetti: Communicable Diseases - diagnosis; Communicable Diseases - drug therapy; Nanoparticles - therapeutic use; Nanoparticle Drug Delivery System; Drug Resistance; Nanomedicine; Parasitology; Bacteria; Virology; Nanobiotechnology
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Intro -- Foreword by Dr. Shahid Jameel -- Foreword by Prof. Abdulhadi Baykal -- Preface -- Contents -- About the Editors -- Part I: Infectious Diseases -- 1: A Holistic View of Human Infectious Diseases: Challenges and Opportunities -- 1.1 Overview -- 1.2 Chain of Infection -- 1.2.1 Infectious Agents -- 1.2.2 Reservoir -- 1.2.3 Modes of Escape -- 1.2.4 Mode of Transmission -- 1.2.5 Direct Contact -- 1.2.5.1 Droplet Transmission -- 1.2.5.2 Indirect Transmission -- Airborne Transmission -- Vehicle Borne Transmission -- Vector Borne Transmission -- 1.2.6 Portal of Entry -- 1.2.7 Susceptible Host -- 1.3 Emerging and Re-emerging Diseases -- 1.3.1 Re-emerging Infectious ; Diseases -- 1.3.2 Factors Contributing to Emergence or Re-emergence of Infectious Diseases -- 1.3.3 Globalization, Trade, and Travelling -- 1.3.4 Environmental and Ecological Changes -- 1.3.5 Human-Reservoir (Wild Animal) Interface -- 1.3.6 Adaptations and Changes of Microbial Agents/Antibiotic Resistance -- 1.4 Interventions for Infectious Disease Control and Prevention -- 1.4.1 Antimicrobials/Antibiotics -- 1.4.2 Vaccines -- 1.4.3 Public Health Priority for Infection Control -- 1.5 New Strategies and Hopes -- 1.5.1 Nanotechnology and Nanobiology -- 1.5.2 Gene Sequencing to Inform Infection Control -- 1.5.3 Data Handling and Simulation Systems -- 1.5.4 Healthcare Reforms -- 1.6 Conclusion -- References -- 2: Application of Nanotechnology in the Treatment of Infectious Diseases: An Overview -- 2.1 Introduction -- 2.2 Nano Formulations for the Treatment of Bacterial Infections -- 2.3 Nano Formulations for the Treatment of Fungal Infections -- 2.4 Application of Nanotechnology Against Viral Infections -- 2.5 Nanotechnology in Drug Delivery Targeting Infectious Diseases -- 2.6 Nanomaterials Vaccines for Infectious Diseases.; 2.7 Nanomaterials in Photothermal Therapy Against Infectious Pathogens -- 2.8 Application of Nanodiamonds in Infectious Diseases -- 2.9 Synergistic Antimicrobial Potentials of Nanomaterials/Nanocomposite in Combination with Other Antimicrobial Agents Against... -- 2.10 Challenges and Future Perspectives -- 2.11 Conclusion -- References -- 3: Understanding the Pharmacology and Pharmacotherapeutics for Infectious Diseases -- 3.1 Introduction -- 3.2 Transmission of Infectious Diseases -- 3.3 Infectious Diseases -- 3.3.1 Bacterial Diseases -- 3.3.2 Fungal Infections -- 3.3.3 Viral Infections -- 3.3.4 Parasitic Infections -- 3.4 Emerging Infectious Diseases -- 3.5 Pharamacotherapeutic Interventions -- 3.5.1 Antibiotics -- 3.5.1.1 Beta Lactam Antibiotics -- 3.5.1.2 Fluoroquinolones -- 3.5.2 Antifungals -- 3.5.3 Antivirals -- 3.5.3.1 Antiviral Targeting the Viral Proteins -- 3.5.3.2 Antivirals Targeting the Host Proteins -- 3.5.4 Antiparasitic Drugs -- 3.6 Nanomedicine -- 3.6.1 Types of Nanoparticles Used in Nanomedicine -- 3.6.1.1 Organic Nanoparticles -- 3.6.1.2 Inorganic Nanoparticles -- 3.6.2 Nanoparticles in Infectious Diseases -- 3.7 Conclusion -- References -- Part II: Nanomaterials as Anti-infection Therapeutics -- 4: Advanced Nanomaterials for Infectious Diseases Therapeutics -- 4.1 Metal-Based Nanoparticles -- 4.1.1 Silver Nanoparticles -- 4.1.2 Gold Nanoparticles -- 4.1.3 Iron-Oxide Based Nanoparticles -- 4.1.4 Zinc Oxide Nanoparticles -- 4.1.5 Copper Oxide Nanoparticles -- 4.2 Encapsulated Nanoparticles -- 4.2.1 Polymer/Dendrimer Encapsulation -- 4.2.2 Metal Encapsulation -- 4.3 Nanoantibiotics -- 4.4 Conclusions and Future Trend -- References -- 5: Metal-Based Nanoparticles for Infectious Diseases and Therapeutics -- 5.1 Introduction -- 5.2 Bacteria and Antibacterial Drug -- 5.3 Metal-Based Nanoparticles.; 5.3.1 Synthesis, Characterization, and Properties of Metal-Based Nanoparticles -- 5.3.2 Classification of Metal-Based Nanoparticles -- 5.3.3 Metal Nanoparticles Against Infectious Diseases -- 5.3.4 Metal Oxide Nanoparticles Against Infectious Diseases -- 5.3.5 Metal Sulfide Nanoparticles Against Infectious Diseases -- 5.4 General Mechanism of Metal-Based Nanoparticles Against Infectious Diseases -- 5.5 Factors Affecting the Antimicrobial Activities of Nanoparticles -- 5.6 Conclusion -- References -- 6: The Future Therapy of Nanomedicine Against Respiratory Viral Infections -- 6.1 Introduction -- 6.2 Viruses Classification According to the Genetic Materials -- 6.3 The Threat of Respiratory Viral Infections -- 6.3.1 The SARS-CoV-2 Threat -- 6.3.2 Toxicity of Conventional Antiviral Drugs -- 6.4 Nanodrugs and Their Efficacy in Killing Viruses -- 6.4.1 Nanomedicine Weapon Against ; SARS-CoV-2 Threat -- 6.4.2 Biogenic and Non-biogenic Metallic Nanoparticles and Its Antiviral Efficiency -- 6.4.3 The Antiviral Activity of Organic Nanoparticles -- 6.4.3.1 Polymeric Nanoparticles -- 6.4.3.2 Carbon-Based Nanomaterials as Antivirals -- 6.4.3.3 Lactoferrin Loaded Nanoparticles as Antivirals -- 6.4.3.4 Silica Nanocarriers as Antivirals -- 6.5 Conclusion -- References -- 7: Application of Nanoparticles to Invasive Fungal Infections -- 7.1 Introduction -- 7.2 Antifungal Therapy -- 7.2.1 Azole Compounds -- 7.2.2 Pyrimidine Analogous -- 7.2.3 Polyenes -- 7.2.4 Echinocandins -- 7.3 Nanoformulations for Antifungal Therapy -- 7.3.1 Polymeric Nanoparticles -- 7.3.2 Metallic Nanoparticles -- 7.3.3 Lipid Nanoparticles -- 7.4 Systemic Mycoses and Nanotechnology -- 7.4.1 Candida sp. -- 7.4.1.1 Polymeric Nanoparticles -- 7.4.1.2 Lipid Nanoparticles -- 7.4.2 Aspergillus sp. -- 7.4.2.1 Polymeric Nanoparticles -- 7.4.3 Cryptococcus sp. -- 7.4.3.1 Polymeric Nanoparticles.; 7.4.3.2 Metallic Nanoparticles -- 7.4.3.3 Lipid Nanoparticles -- 7.4.4 Paracoccidioides sp. -- 7.4.4.1 Polymeric Nanoparticles -- Polymeric Nanoparticles Used in Vaccines -- 7.4.4.2 Metallic Nanoparticles -- 7.4.4.3 Lipid Nanoparticles -- 7.5 Conclusion -- References -- 8: Nanomaterials in the Diagnosis and Treatment of Leishmaniasis -- 8.1 Introduction -- 8.2 Available Chemotherapeutic Drugs for Leishmaniasis -- 8.2.1 Pentavalent Antimonial -- 8.2.2 Pentamidine -- 8.2.3 Amphotericin B -- 8.2.4 Miltefosine -- 8.2.5 Paromomycin -- 8.2.6 Sitamaquine -- 8.2.7 Other New Antileishmanial Molecules -- 8.3 Conventional Methods for Detection of Leishmaniasis -- 8.4 Nanomaterials in the Diagnosis of Leishmaniasis -- 8.5 Nanomaterials in the Therapy and Protection Against Leishmania spp. Infection -- 8.5.1 Antileishmanial Nanoparticles and Nanopreparations -- 8.5.2 Nanomaterials in the Development of Vaccine Against Leishmaniasis -- 8.6 Conclusion -- References -- 9: A Comprehensive Review on the Synthesis, Surface Decoration of Nanoselenium and Their Medical Applications -- 9.1 Introduction -- 9.2 Chemical Synthesis of SeNPs -- 9.2.1 Chemical Reduction Methods -- 9.2.2 Wet Chemical Method -- 9.2.3 Hydrothermal Methods -- 9.2.4 Solvothermal Method -- 9.2.5 Sol-Gel Method -- 9.3 Physical Synthesis of SeNPs -- 9.3.1 Lser bltin -- 9.3.2 Microwave Irradiation Method -- 9.3.3 Sonochemical (Ultrasonic) -- 9.3.4 Gamma Radiation -- 9.3.5 Low Temperature Reactive Aerosol Processing -- 9.3.6 Heterogeneous Condensation Method -- 9.3.7 Ball Milling Method -- 9.4 Biological Synthesis of SeNPs -- 9.5 Antimicrobial Activity and Mechanism of SeNPs -- 9.6 Surface Decoration of SeNPs -- 9.6.1 5-Fluorouracil (5-FU) -- 9.6.2 Polyporus rhinoceros -- 9.6.3 Chitosan -- 9.6.4 Other Amino Acids -- 9.6.5 Proteins or Polypeptide -- 9.6.6 Natural Products -- 9.7 Conclusion -- References.; Part III: Nanotechnology and Drug Carriers -- 10: Nanotechnology in Drug Delivery Systems: Ways to Boost Bioavailability of Drugs -- 10.1 Introduction -- 10.2 Nanotechnology Oriented Drug Delivery Systems -- 10.3 Nanoparticles as Drug Carrier -- 10.4 Quantum Dots Nanocarriers -- 10.5 Electrospun Nanofibers as Carriers -- 10.6 Nanoemulsions for Delivery of Drugs -- 10.7 Nanohydrogel Delivery Systems -- 10.8 Conclusion -- References -- 11: Recent Developments in Silica Nanoparticle Based Drug Delivery System -- 11.1 Introduction -- 11.2 Types of Silica Nanoparticles -- 11.3 Non-porous Silica Nanoparticle -- 11.4 Mesoporous Silica Nanoparticles -- 11.5 Core/Shell Silica Nanoparticles -- 11.6 Synthesis of Silica Nanoparticles -- 11.7 Mesoporous Silica Nanoparticles as Drug Delivery System -- 11.8 pH Responsive MSN Based Carrier System -- 11.9 Redox ; Responsive Nanocarrier -- 11.10 Enzyme Responsive Nanocarrier -- 11.11 Silica Nanoparticle as a DDS for Infectious Diseases -- 11.12 Beneficial Attributes of NPs for Treatment of Infectious Diseases -- 11.13 Specific Properties of MSN Due to Which they are Used as a Nanocarrier for Infectious Disease Treatment -- 11.14 Biocompatibility, Biodistribution, and Clearance of Silica Nanoparticles -- References -- 12: Nano Drug Delivery Approaches for Lymphatic Filariasis Therapeutics -- 12.1 Introduction -- 12.2 Pathophysiological Aspects of Lymphatic Filariasis and Drug Based Targeting -- 12.3 Nanomedicine as Advanced Tool for Targeting -- 12.3.1 Nanotechnology for Overcoming Anatomical Barriers -- 12.3.1.1 In the Treatment of Adult Stage Filariasis Through Targeted Nano Drug Delivery System -- 12.3.1.2 Nanotherapeutic Amplification of MIF Effectiveness to Stop the Conduction of Lymphatic Filariasis -- 12.3.2 Nanotechnology as Enhancing the Physiochemical Properties.; 12.3.2.1 Nanoscientific Elucidation for Poor Solubility of Anti-filarial Agents.
• Sommario/riassunto: This book aims to cover the applications of nanotechnology against human infectious diseases. The chapters of the book discuss the role of nanotechnology in the efficient diagnosis and treatment of these diseases. It explicitly provides an overview of nanodiagnostics for infectious diseases from nanoparticles-based, nanodevice-based, and point-of-care platforms. The book also covers the state-of-the-art review of recent progress in biomimetic and bioengineered nanotherapies to treat infectious diseases. It also presents a nano carrier-based CRISPR/Cas9 delivery system for gene editing and its applications for developing interventional approaches against communicable diseases. Further, it reviews the recent developments in nanotechnology to engineer nanoparticles with desired physicochemical properties as a line of defense against multi-drug resistance micro-organisms. Cutting across the disciplines, this book serves as a guide for researchers in biotechnology, parasitology, and nanotechnology.